JP2008524136A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524136A5 JP2008524136A5 JP2007545905A JP2007545905A JP2008524136A5 JP 2008524136 A5 JP2008524136 A5 JP 2008524136A5 JP 2007545905 A JP2007545905 A JP 2007545905A JP 2007545905 A JP2007545905 A JP 2007545905A JP 2008524136 A5 JP2008524136 A5 JP 2008524136A5
- Authority
- JP
- Japan
- Prior art keywords
- telmisartan
- composition
- composition according
- hydrochlorothiazide
- angiotensin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 20
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 12
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 12
- 229960005187 telmisartan Drugs 0.000 claims 12
- 210000002966 serum Anatomy 0.000 claims 9
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 8
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 7
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000002934 diuretic Substances 0.000 claims 5
- 230000001882 diuretic effect Effects 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- -1 pH regulators Substances 0.000 claims 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 102100028255 Renin Human genes 0.000 claims 2
- 108090000783 Renin Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003086 colorant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 229960002920 sorbitol Drugs 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical group 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 239000011888 foil Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229920001903 high density polyethylene Polymers 0.000 claims 1
- 239000004700 high-density polyethylene Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940060367 inert ingredients Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical group 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940083608 sodium hydroxide Drugs 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000007944 soluble tablet Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63706204P | 2004-12-17 | 2004-12-17 | |
| PCT/EP2005/013224 WO2006063737A1 (en) | 2004-12-17 | 2005-12-09 | Combination therapy comprising telmisartan and hydrochlorothiazide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524136A JP2008524136A (ja) | 2008-07-10 |
| JP2008524136A5 true JP2008524136A5 (enExample) | 2009-02-05 |
Family
ID=35589356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545905A Pending JP2008524136A (ja) | 2004-12-17 | 2005-12-09 | テルミサルタンとヒドロクロロチアジドを含む併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1827424A1 (enExample) |
| JP (1) | JP2008524136A (enExample) |
| KR (1) | KR20070097511A (enExample) |
| CN (1) | CN101080225A (enExample) |
| AR (1) | AR052052A1 (enExample) |
| AU (1) | AU2005315855A1 (enExample) |
| BR (1) | BRPI0519656A2 (enExample) |
| CA (1) | CA2589493A1 (enExample) |
| EA (1) | EA200701159A1 (enExample) |
| IL (1) | IL183944A0 (enExample) |
| NO (1) | NO20072325L (enExample) |
| PE (1) | PE20060768A1 (enExample) |
| TW (1) | TW200637546A (enExample) |
| UY (1) | UY29274A1 (enExample) |
| WO (1) | WO2006063737A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| RU2465916C2 (ru) * | 2007-10-19 | 2012-11-10 | Оцука Фармасьютикал Ко., Лтд. | Твердый фармацевтический препарат матричного типа |
| WO2009058950A2 (en) | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| EP2252273B1 (en) | 2008-03-19 | 2016-12-28 | ratiopharm GmbH | Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| WO2010013835A2 (en) * | 2008-07-31 | 2010-02-04 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition |
| GB0822170D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Telmisartan with diuretic formulations |
| WO2010146187A2 (en) | 2009-06-19 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
| WO2011002423A2 (en) * | 2009-07-02 | 2011-01-06 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| WO2011002425A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgig Mahmut | Pharmaceutical composition increasing solubility and stability |
| TR200906506A2 (tr) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Telmisartan içeren katı dozaj formları. |
| WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| EP2952196A4 (en) * | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE |
| JP6422868B2 (ja) | 2013-07-23 | 2018-11-14 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
| CN106562973A (zh) * | 2016-11-06 | 2017-04-19 | 成都先先先生物科技有限公司 | 一种抗高血压药物复方制剂 |
| CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢氯噻嗪的共晶 |
| CN108653227A (zh) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | 一种替米沙坦氢氯噻嗪片及其制备方法 |
| EP4029867A1 (en) * | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4229085C2 (de) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Längliche, teilbare Tablette |
| ES2445041T3 (es) * | 2002-01-16 | 2014-02-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Método para la preparación de telmisartán amorfo |
-
2005
- 2005-12-09 CA CA002589493A patent/CA2589493A1/en not_active Abandoned
- 2005-12-09 EP EP05814002A patent/EP1827424A1/en not_active Withdrawn
- 2005-12-09 WO PCT/EP2005/013224 patent/WO2006063737A1/en not_active Ceased
- 2005-12-09 AU AU2005315855A patent/AU2005315855A1/en not_active Abandoned
- 2005-12-09 EA EA200701159A patent/EA200701159A1/ru unknown
- 2005-12-09 BR BRPI0519656-6A patent/BRPI0519656A2/pt not_active Application Discontinuation
- 2005-12-09 CN CNA2005800434334A patent/CN101080225A/zh active Pending
- 2005-12-09 JP JP2007545905A patent/JP2008524136A/ja active Pending
- 2005-12-09 KR KR1020077016354A patent/KR20070097511A/ko not_active Withdrawn
- 2005-12-15 PE PE2005001465A patent/PE20060768A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144909A patent/TW200637546A/zh unknown
- 2005-12-16 AR ARP050105303A patent/AR052052A1/es unknown
- 2005-12-20 UY UY29274A patent/UY29274A1/es not_active Application Discontinuation
-
2007
- 2007-05-04 NO NO20072325A patent/NO20072325L/no not_active Application Discontinuation
- 2007-06-14 IL IL183944A patent/IL183944A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524136A5 (enExample) | ||
| CN111405895B (zh) | 一种控释药物组合物及其制备方法 | |
| EP1515701B1 (en) | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide | |
| RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
| JP6993502B2 (ja) | Ｓｇｌｔ－２阻害剤とアンジオテンシン受容体拮抗薬を含む医薬組成物 | |
| CN101641084B (zh) | 药物组合物 | |
| US20060110450A1 (en) | Bilayer tablet of telmisartan and amlodipine | |
| CN102065847A (zh) | 含有血管紧张素-ⅱ受体阻断剂的药物制剂 | |
| EP1718281A1 (en) | Multilayer tablet | |
| EA019471B1 (ru) | Твердая фармацевтическая композиция, содержащая амлодипин и лозартан | |
| CN101450211A (zh) | 复方降压制剂 | |
| WO2006063737A1 (en) | Combination therapy comprising telmisartan and hydrochlorothiazide | |
| WO2022036506A1 (zh) | Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途 | |
| WO2014191321A1 (en) | Solid pharmaceutical dosage form | |
| KR101512386B1 (ko) | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 | |
| EP1673107B1 (en) | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | |
| TW201414511A (zh) | 含有厄貝沙坦（ｉｒｂｅｓａｒｔａｎ）及ｈｍｇ－ｃｏａ還原酶抑制劑之藥學的複合膠囊調配物 | |
| JP2015091830A (ja) | 有機化合物のガレヌス製剤 | |
| KR20200058865A (ko) | 이층정제 및 이의 제조 방법 | |
| TWI867128B (zh) | 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途 | |
| US7625940B2 (en) | Method of treating hypertension with a very low dose of chlorthalidone | |
| CN112294771B (zh) | 速放医药组合物 | |
| WO2008134047A1 (en) | Methods of treating hypertension | |
| CA3235787A1 (en) | Methods of treating patients having type 1 diabetes with eflornithine | |
| WO2022070209A1 (en) | Biphasic release fixed dose combination formulations |